Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central anxious program, conolidine modulates alternate molecular targets. A Science Developments review located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability... https://mannersd120ujq7.nico-wiki.com/user